维生素E改善非酒精性脂肪性肝炎合并晚期纤维化患者的无移植生存率和肝功能失代偿
在印第安纳大学医学中心2004年10月至2016年1月间活检证实的非酒精性脂肪性肝炎(NASH)合并桥接纤维化或肝硬化患者236例中,90例每日服用800国际单位维生素E至少2年者经倾向性匹配与90例未服用者比较。维生素E使用者调整后无移植生存率更高(78% vs 49%,P<0.01),肝功能失代偿率更低(37% vs 62%,P=0.04);调整后死亡或移植风险降低(调整后风险比0.30,95%CI 0.12-0.74,P<0.01),肝功能失代偿风险降低(调整后亚风险比0.52,95%CI 0.28-0.96,P=0.036)。
要点
- NASH合并桥接纤维化或肝硬化患者使用维生素E与更高的调整后无移植生存率相关(78% vs 49%,P<0.01)。
- 维生素E使用者肝功能失代偿率更低(37% vs 62%,P=0.04),调整后亚风险比0.52(95%CI 0.28-0.96)。
- 维生素E治疗与死亡或移植风险降低相关(调整后风险比0.30,95%CI 0.12-0.74),该获益在合并和不合并糖尿病患者中均可见。
核心结论
- 维生素E使用与NASH合并桥接纤维化或肝硬化患者临床结局改善相关。
研究设计与样本
- 在印第安纳大学医学中心2004年10月至2016年1月间入选236例活检证实的NASH合并桥接纤维化或肝硬化患者。
- 其中90例每日服用800国际单位维生素E至少2年者为维生素E使用者,经倾向性匹配与90例未服用维生素E的对照者比较,匹配调整了纤维化严重程度、年龄、性别、体重指数、合并症及其治疗、低密度脂蛋白胆固醇、肝脏生化指标和维生素E随访时间。
主要发现
- 维生素E使用者和对照者的中位随访时间分别为5.62年(四分位距4.3-7.5)和5.6年(四分位距4-6.9)。
- 维生素E使用者调整后无移植生存率高于对照者(78% vs 49%,P<0.01)。
- 维生素E使用者肝功能失代偿率低于对照者(37% vs 62%,P=0.04)。
- 控制纤维化严重程度、患者入组日历年和其他潜在混杂因素后,维生素E治疗降低死亡或移植风险(调整后风险比0.30,95%CI 0.12-0.74,P<0.01)和肝功能失代偿风险(调整后亚风险比0.52,95%CI 0.28-0.96,P=0.036)。
- 这些获益在合并糖尿病和不合并糖尿病的患者中均可见;维生素E暴露患者与对照者调整后10年肝细胞癌、血管事件和非肝脏癌症的累积概率无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vitamin E improves liver histology in adults with nonalcoholic steatohepatitis (NASH) but not diabetes, but its impact on long-term patient outcomes is unknown. We evaluated whether vitamin E treatment improves clinical outcomes of NASH patients with bridging fibrosis or cirrhosis. Two hundred and thirty-six patients with biopsy-proven NASH and bridging fibrosis or cirrhosis seen at Indiana University Medical Center between October 2004 and January 2016 were included. Ninety of them took 800 international units/day of vitamin E for ≥2 years (vitamin E users) and were propensity-matched to 90 adults who did not take vitamin E (controls) after adjusting for fibrosis severity, age, gender, body mass index, comorbidities and their treatment, low-density lipoprotein cholesterol, liver biochemistries, and length of follow-up on vitamin E. Covariate-adjusted Cox and competing risk regression models were assessed to evaluate the association between vitamin E treatment and patient outcomes. The median follow-up was 5.62 (interquartile range [IQR], 4.3-7.5) and 5.6 (IQR, 4-6.9) years for vitamin E users and controls, respectively. Vitamin E users had higher adjusted transplant-free survival (78% versus 49%, P < 0.01) and lower rates of hepatic decompensation (37% versus 62%, P = 0.04) than controls. After controlling for severity of fibrosis, calendar year of patient enrollment, and other potential confounders, vitamin E treatment decreased the risk of death or transplant (adjusted hazard ratio, 0.30; 95% confidence interval [CI], 0.12-0.74; P < 0.01) and hepatic decompensation (adjusted sub-HR, 0.52; 95% CI, 0.28-0.96; P = 0.036). These benefits were evident in both those with diabetes and those without diabetes. Adjusted 10-year cumulative probabilities of hepatocellular carcinoma, vascular events, and nonhepatic cancers were not different between vitamin E-exposed patients and controls. Conclusion: Vitamin E use was associated with improved clinical outcomes in patients with NASH and bridging fibrosis or cirrhosis.
引用
- Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology. 2019. PMID: 30506586. doi:10.1002/hep.30368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。